Newsletter registration

Austria.
Dynamic Business Location.

New IMP building: International research center opens in Vienna

opening ceremony at IMP © IMP

Philipp von Lattorff explains that Boehringer Ingelheim, in its capacity as a family-owned company, has the financial means to support basic research which may first lead to the development of new drugs in the long run. “IMP is the most important investment of Boehringer Ingelheim in basic research”, says the Managing Director of Boehringer Ingelheim RCV.

About IMP

The Research Institute of Molecular Pathology (IMP) in Vienna is a basic biomedical research institute largely sponsored by the international Boehringer Ingelheim group of companies With over 200 scientists from 40 nations, the IMP is committed to scientific discovery of fundamental molecular and cellular mechanisms in order to provide detail knowledge of complex biological phenomena. The IMP is a founding member of the Vienna Biocenter, Austria’s beacon in the international elite of top molecular-biological research.

About Boehringer Ingelheim Regional Center Vienna

The Boehringer Ingelheim Regional Center Vienna is responsible for Boehringer Ingelheim’s business with prescription drugs and animal medicines in Austria and over 30 other countries in Central and Eastern Europe, Central Asia, Switzerland and Israel. Moreover, the entire clinical research of the region is managed from Vienna. Vienna is the center for cancer research and also a location for biopharmaceutical research, development and production in the Group. Boehringer Ingelheim is also involved in basic research and is represented in this field by the Research Institute of Molecular Pathology Vienna (IMP). Thus, Boehringer Ingelheim is among Austria’s most research intensive pharmaceutical companies. The Regional Center Vienna generated net sales of EUR 760.2 million in the business year 2015 and employed 3,403 employees in the Central and Eastern European region, 1,501 of whom are in Austria.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

Austria Map

Find the perfect location for your company

One of Austria's key strengths as a business destination is its highly qualified and motivated skilled workforce for research and development, especially in the scientific sector.

Nestlé Austria

Logo
More testimonials

news from the business location Austria

Zika Virus: Testing for Austria vaccine begins

A promising vaccine for the Zika virus is now being tested by Themis Bioscience GmbH, a specialized biotech company developing prophylactic vaccines against emerging tropical infectious diseases. After recent progress with the development of a Chikungunya vaccine the company succeeded in swiftly adapting their proprietary vaccine technology for their Zika vaccine program. This program is based on a live attenuated recombinant vaccine that promises a fast and effective immune response.

Foreign companies as a driving force for Austria

Austria is a very successful country economically speaking. Only Luxembourg, Ireland and the Netherlands have a higher per capita GDP in the EU. Domestic companies mainly assert themselves as market leaders in small niches, are highly productive and export almost everywhere in the world. This is something which is well known, at least within Austria itself.

More news All blog posts